ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1063

Elevated Serum and Urinary Secreted Protein Acidic and Rich in Cysteine (SPARC) Levels Are Novel Biomarkers of Kidney Fibrosis Severity

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Yangyang, Niu, Shanghai Tongji Hospital, Shanghai, Shanghai, China

Interstitial fibrosis is the main determinant of the progression of chronic kidney disease (CKD), and noninvasive identification of interstitial fibrosis is a major challenge. We aimed to explore the diagnostic value of serum and urinary secreted protein acidic and rich in cysteine (SPARC) in kidney fibrosis.


674 renal biopsy CKD patients in 1 clinical center serving as the training cohort (n = 322) and in 3 clinical centers serving as the validation cohort (n = 352). The serum and urinary SPARC levels were measured at the time of kidney biopsy. In vivo and in vitro kidney fibrosis models were also applied to confirm the role of SPARC.


Increased SPARC expression was found in kidney fibrosis tissues. Higher serum and urinary SPARC levels were detected in the kidney fibrosis group than nonkidney fibrosis group. The higher levels of serum SPARC were associated with increasing severity of kidney fibrosis. Moreover, the serum SPARC level had a higher area under the receiver operating characteristic curve (AUC-ROC) (AUC 0.86) than urinary SPARC and the estimated glomerular filtration rate (eGFR). The combination of serum SPARC, urinary SPARC and eGFR could increase the AUC-ROC for kidney fibrosis from 0.86 to 0.90. The diagnostic performance of serum or urinary SPARC were consistent in the validation cohort. In vivo and in vitro kidney fibrosis models also confirmed the upregulation of SPARC expression.


Serum and urinary SPARC levels may be potential biomarkers for kidney fibrosis, which may be helpful for the noninvasive diagnosis of kidney fibrosis.


  • Private Foundation Support